Influential factors of serum concentration/dosage ratio for schizophrenia patients after oral administration of olanzapine

doi:10.12092/j.issn.1009-2501.2019.09.010

Abstract

Abstract:

AIM: To investigate the factors affecting the serum concentration/dose ratio of olanzapine in schizophrenic patients. METHODS: The data of 304 schizophrenic inpatients in our hospital in 2018 were retrospectively collected, and the patients' medical records and medical orders were consulted. The C/D values of olanzapine were calculated. The effects of gender, age, BMI, source of olanzapine (domestic or imported), smoking, combined use of drugs and CYP1A2 metabolic enzyme genotype polymorphism on the C/D values were studied. RESULTS:The C/D mean value of male patients was (2.59±1.08) ng·mL-1·mg-1·d, and that of female patients was (3.14±1.80) ng·mL-1·mg-1·d. The C/D mean of female patients was significantly higher than that of male patients (P=0.032). The combination of hepatic enzyme inducers or inhibitors could significantly affect the C/D value of patients. Smoking could significantly reduce the C/D value of patients (P=0.024). The C/D value of patients with different ages and CYP1A2 genotype showed no significantly difference. BMI and the source of olanzapine (domestic or imported) had no significant effect on the C/D value of patients. CONCLUSION:The C/D value of olanzapine is mainly related to the gender of patients and the combination of drugs and smoking, and the genotype of patients should be fully considered.

Key words: olanzapine, schizophrenia, serum drug concentration/dose ratio, genotype

CLC Number:

WAN Ping, LIU Liang, ZHANG Ping, ZHANG Zhongdong. Influential factors of serum concentration/dosage ratio for schizophrenia patients after oral administration of olanzapine[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1024-1029.

References

［1］赵瑾，张燕，晁阳阳，等. 利培酮和奥氮平对首发精神分裂症患者治疗前后认知功能的对比观察［J］．中华医学杂志，2016，96（37）：2960-2964．
［2］江斌，史克银．利培酮和奥氮平长疗程治疗对女性精神分裂症患者血清催乳素的影响［J］．医药导报，2016，35（10）：1079-1081．
［3］崔力军，潘鑫，朱洁琳，等．帕利哌酮与奥氮平治疗首发精神分裂症患者的疗效观察［J］．中国临床药理学与治疗学，2017，22（4）：466-470．
［4］韩攸村，黄同旭．帕利哌酮缓释剂与奥氮平治疗精神分裂症疗效及对认知功能影响对照研究［J］．精神医学杂志，2017，27（1）：53-55．
［5］张爱慧．奥氮平治疗老年精神分裂症患者的临床疗效及对认知功能的改善作用［J］．实用临床医药杂志，2017，21（1）：154-155．
［6］赵绍锋．奥氮平对精神分裂症患者认知功能障碍的改善作用［J］．中国实用神经疾病杂志，2017，20（16）：78-80．
［7］张巧真，黄敏芳，宋伟明．4969例奥氮平血药浓度日常检测及药师干预分析［J］．现代实用医学，2018，30（4）：492-493．
［8］周云飞．影响氯氮平的血药浓度、疗效及副反应因素的研究进展［J］．中华精神科杂志，2002，35（4）：248-249．
［9］程晓平，古梓婷，钱立豪，等．奥氮平对精神分裂症患者生活质量影响的Meta分析［J］．中国民康医学，2016，28（12）：63-66，+70．
［10］丰丽莼，杨博涵，王雪芹，等．UPLC-MS /MS 法测定人血浆中奥氮平、利培酮和帕潘立酮的浓度［J］．中国药房，2017，28（8）：1045-1047．
［11］张付全，王军，王国强，等．低剂量奥氮平抗抑郁增效作用及对自主神经功能影响的对照研究［J］．临床精神医学杂志，2017，27（1）：41-43．
［12］马燕，李方捷，毛叶萌．我中心奥氮平致不良反应报告分析［J］．中国药房，2013，24（24）：2335-2336．
［13］李彪，迟正锁，陈贝，等．氨磺必利、帕利哌酮缓释片、奥氮平对首发未用药精神分裂症患者认知、记忆功能的影响［J］．国际精神病学杂志，2015，42（5）：14-17．
［14］牛莉莉，温科奇，熊鹏，等．首发精神分裂症治疗前后血清NGF、BDNF、GFAP与临床症状的相关性研究［J］．精神医学杂志，2015，28（1）：10-12．
［15］陈寅，施薇华.精神病专科医院509例药物不良反应分析［J］．中国执业药师，2016，13（10）：49-53．
［16］程晓平，古梓婷，钱立豪，等．奥氮平对精神分裂症患者生活质量影响的Meta分析［J］．中国民康医学，2016，28（12）：63-66．
［17］凌迎春，林秀琴，周月琴，等．精神分裂症患者奥氮平血药浓度与临床的关系［J］．中国基层医药，2014，21（9）：1398-1399．
［18］王锐．观察奥氮平治疗精神分裂症的剂量、血药浓度与临床疗效、药物副反应的关系研究［J］．医药前沿，2016，6（9）：227-228．
［19］温全胜，张传福，卢文芬，等．精神分裂症患者奥氮平治疗的剂量、血药浓度及临床效应之间的关系研究［J］．北方药学，2015，1（2）：103-104．
［20］Laika B, Leucht S, Heres S, et al. Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome［J］. Pharmacogenomics J, 2010, 10(1): 20-29.

[1]	LI Na, HAN Hongcan, WANG Jun. General considerations for bioequivalence studies with pharmacokinetic methods for anti-schizophrenic drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1419-1425.
[2]	YAN Pan, SHI Jianfei, LI Jing, WANG Shengdong, WANG Shuqi, WANG Chengpeng, SONG Mingfen. Effects of DRD2 and 5-HTR2A gene polymorphisms and their interaction on olanzapine in the treatment of schizophrenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(10): 1131-1138.
[3]	FAN Yao, XUE Yong, WANG Xin, CHEN Xuefei, ZHANG Xu, YAO Yingshui, SHEN Chong. Association analysis of apolipoprotein E polymorphisms and weight loss among schizophrenia patients with risperidone treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 288-295.
[4]	CAO Ting, LI Nana, CAI Hualin. Progress in neurosteroids related to the pathogenesis and treatment of schizophrenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 709-714.
[5]	ZHOU Jianhua, LIU Kelan, WU Ganbin. Effects of anti-platelet individual treatment guided by CYP2C19 polymorphism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(12): 1364-1367.
[6]	ZHANG Xiaoying, WANG Kang, WU Sha, GUO Peng. Association analysis of low dose olanzapine in controlling mental symptoms of NMDAR encephalitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(11): 1292-1296.
[7]	CUI Lijun, PAN Xin, ZHU Jielin, LI Jianhua. Effect of paliperidone and olanzapine on patients with first-episode schizophrenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(4): 466-470.
[8]	ZHOU Yong, Chen Xuefang, HUANG Hanjin. Efficacy and safety of amisulpride for schizophrenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(10): 1152-1157.
[9]	LI Xiao-ning, YANG Zheng-hai, LI Jing. Study of different genotypes hepatitis C virus non-structural 3 protein on telomerase activity [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(2): 128-131.
[10]	HANG Rong-hua, LI Ye-ping, WU Ming-fei, LI Rui. Relationship on medication compliance, antipsychotic side-effects and social support in schizophrenia outpatients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(8): 912-915.
[11]	NI Ping, LV Hai-long, GUO Xiao-feng, ZHANG Li-li, XU Lin-yong. Comparison of curative effect and clinical influence factors of risperidone and olanzapine in the treatment of acute phrase of schizophrenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(2): 182-185.
[12]	YU Ling-yan, LOU Hong-gang, RUAN Zou-rong, JIANG Bo, CHEN Jin-liang. Correlation analysis of olanzapine plasma concentrations and individual intrinsic factors based on PLS model [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(9): 1022-1025.
[13]	ZHANG Yu-qi, XU Wen-wei, CHENG Zao-huo, WU Yue, GU Jun, TANG Li, JI Ping, LI Gui-lin. Efficacy and safety study of the donepezil combined olanzapine flow in the treatment of behavioral and psychological symptoms of dementia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(9): 1038-1041.
[14]	ZHONG Zhi-yong, ZHANG Ming, WANG Ji-hui, WU Xiao-li. A retrospective study of risperidone oral solution versus olanzapine tablets in treating brain organic mental disorders [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(9): 1047-1051.
[15]	TANG Ya-mei, ZHANG Xiang-hui, LIU Yong. Concentration change of NE, 5-HT and their metabolites in brain tissue in schizophrenia developmental models rat repeatedly treated with MK-801 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(7): 721-726.